PMID: 15353425Sep 9, 2004Paper

Cost-effectiveness of cardiac resynchronization therapy in patients with symptomatic heart failure

Annals of Internal Medicine
Graham NicholJohn F P Bridges

Abstract

Heart failure is a common, costly, and debilitating illness. Resynchronization of ventricular contraction in patients with heart failure improves ejection fraction. The long-term morbidity and costs associated with such cardiac resynchronization therapy remain unclear. To assess the incremental cost-effectiveness of cardiac resynchronization therapy. Markov model with Monte Carlo simulation. Future costs and effects were discounted at 3%. Effects data were obtained from a concurrent systematic review. Health-related quality-of-life and cost data were obtained from publicly available data or from surveys. Patients with reduced ventricular function and prolonged QRS. Lifetime. U.S. health care system. Cardiac resynchronization therapy versus medical therapy. Quality-adjusted life-years (QALYs), costs, and incremental cost-effectiveness. Medical therapy yielded a median of 2.64 (interquartile range, 2.47 to 2.82) discounted QALYs and a median discounted lifetime cost of 34,400 dollars (interquartile range, 31,100 dollars to 37,700 dollars). Cardiac resynchronization therapy was associated with a median incremental cost of 107,800 dollars(interquartile range, 79,800 dollars to 156,500 dollars) per additional QALY. Results were sens...Continue Reading

Citations

Feb 27, 2007·Journal of Interventional Cardiac Electrophysiology : an International Journal of Arrhythmias and Pacing·Giuseppe BorianiAngelo Branzi
Mar 5, 2011·Journal of Interventional Cardiac Electrophysiology : an International Journal of Arrhythmias and Pacing·John Rickard, Bruce Larry Wilkoff
Sep 26, 2012·International Journal of Technology Assessment in Health Care·Rosana PoggioSantiago Miriuka
Apr 15, 2005·The New England Journal of Medicine·John A Jarcho
Aug 31, 2006·International Journal of Clinical Practice·M W H Behan, C A Rinaldi
Mar 25, 2006·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Adrienne HeereyKaren James
Oct 13, 2010·PharmacoEconomics·Mario EandiGiuseppe Pontoriero
Jan 25, 2012·Applied Health Economics and Health Policy·Sergio IannazzoSilvia Chiroli
Apr 10, 2014·Health Care Management Science·Pai Liu, Shinyi Wu
Nov 22, 2012·Heart Failure Clinics·Dhruv S Kazi, Daniel B Mark
May 10, 2011·The Medical Clinics of North America·Ali Ahmed
May 14, 2008·Progress in Cardiovascular Diseases·Ilan Goldenberg, Arthur J Moss
Oct 2, 2007·Heart Failure Clinics·Jordana Kron, Jamie B Conti
Nov 28, 2006·Clinics in Geriatric Medicine·Jordana Kron, Jamie B Conti
Nov 23, 2015·Cardiology Clinics·Hussein Abu DayaPrem Soman
Feb 1, 2011·Echocardiography·Xuedong ShenDennis J Esterbrooks
Nov 9, 2004·Lancet·Richard G TrohmanSergio L Pinski
Dec 20, 2005·Journal of Cardiac Failure·Paul A Heidenreich
Dec 6, 2005·Journal of the American College of Cardiology·W H Wilson Tang, Gary S Francis
Nov 23, 2006·Journal of the American College of Cardiology·Ravi G AssomullDudley J Pennell
Aug 20, 2011·Journal of the American College of Cardiology·Leon A CannizzaroAdrian F Hernandez
Nov 6, 2014·Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology·Giovanni B ForleoFrancesco Romeo
Nov 5, 2013·The Canadian Journal of Cardiology·Ratika ParkashUNKNOWN Canadian Cardiovascular Society
Jul 28, 2016·Pacing and Clinical Electrophysiology : PACE·Raffaele CorbisieroDavid Muller
Jun 3, 2006·Clinical Cardiology·Fred M Kusumoto, Nora Goldschlager
Jul 11, 2013·Circulation. Cardiovascular Quality and Outcomes·Cyrena T SimonsMark A Hlatky
May 7, 2015·Circulation. Cardiovascular Quality and Outcomes·Kouta ItoNiteesh K Choudhry
Nov 7, 2006·The American Heart Hospital Journal·Carlos M FerrarioUNKNOWN CONTROL Trial Investigators
Jan 13, 2006·Preventive Cardiology·Kathryn A GlatterMatthew D McElvany
Dec 16, 2006·Congestive Heart Failure·Samuel F SearsJamie B Conti

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

The New England Journal of Medicine
John ClelandCardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators
The New England Journal of Medicine
Michael R BristowComparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators
The New England Journal of Medicine
William AbrahamMIRACLE Study Group. Multicenter InSync Randomized Clinical Evaluation
© 2021 Meta ULC. All rights reserved